Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
172 StarkeD
Primary candidates include patients with type 2 diabetes and established cardiovascular disease, those with multiple cardiovascular risk factors including dyslipidemia, and adults with obesity or overweight with weight-related comorbidities
To remain competitive, cost estimates for these new drug approvals are expected to be between $10,000 and $18,000 annually at wholesale acquisition cost
No adjustment period is needed since the active ingredient is identical
Official availability also provides access to up-to-date formulation details, usage information, and batch-controlled production processes
Li S, Li Q, Li Y, Li L, Tian H, Sun X
US$ 26.15
US$ 26.15
US$ 22.01
US$ 20.46
US$ 23.39
US$ 24.87
